Cercar
01/05/2022
Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma
Garcia-Melendo, C, Morales-Munera, CE, Dalmau, J, Cubiro, X, Lopez-Sanchez, C, Mozos, A, Yelamos, O. Extensive lichen planopilaris as exclusive lichenoid reaction secondary to pembrolizumab in a patient with metastatic melanoma. Dermatologic Therapy. 2022; 35(5)DOI:10.1111/dth.15388. PMID:35174945. IF:3.600(Q1/3D).
03/04/2022
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis
Reich, K, Conrad, C, Kristensen, LE, Smith, SD, Puig, L, Rich, P, Sapin, C, Holzkaemper, T, Koppelhus, U, Schuster, C. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(3)DOI:10.1080/09546634.2021.1892024. PMID:33641593. IF:2.900(Q2/4D).
01/04/2022
Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome
Iznardo, H, Bredrup, C, Bernal, S, Gladkauskas, T, Mascaro, JM, Roe, E, Baselga, E. Clinical and molecular response to dasatinib in an adult patient with Penttinen syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS PART A. 2022; 188(4)DOI:10.1002/ajmg.a.62603. PMID:34894066. IF:2.000(Q3/8D).
01/02/2022
Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
del Alcazar, E, Lopez-Ferrer, A, Martinez-Domenech, A, Ruiz-Villaverde, R, Llamas-Velasco, MD, Rocamora, V, Julia, M, Notario, J, Fernandez-Freire, LR, Sahuquillo-Torralba, A, Vidal, D, Rivera, R, Carretero, G, Mateu, A, de la Cueva, P, Carrascosa, JM. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group. Dermatologic Therapy. 2022; 35(2)DOI:10.1111/dth.15231. PMID:34820971. IF:3.600(Q1/3D).
01/02/2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial
Thaci, D, Strober, B, Gordon, KB, Foley, P, Gooderham, M, Morita, A, Papp, KA, Puig, L, Menter, MA, Colombo, MJ, Elbez, Y, Kisa, RM, Ye, JN, Napoli, AA, Wei, L, Banerjee, S, Merola, JF, Gottlieb, AB. Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial. Dermatology and Therapy. 2022; 12(2)DOI:10.1007/s13555-021-00649-y. PMID:35025062. IF:3.400(Q2/3D).
01/01/2022
Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
Armstrong, AW, Soliman, AM, Betts, KA, Wang, Y, Gao, YW, Stakias, V, Puig, L. Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy. 2022; 12(1)DOI:10.1007/s13555-021-00647-0. PMID:34862951. IF:3.400(Q2/3D).
01/01/2022
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis
Krueger, J, Puig, L, Thaci, D. Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1)DOI:10.1007/s40257-021-00658-9. PMID:35061230. IF:7.300(Q1/1D).
01/01/2022
Pathophysiology of Generalized Pustular Psoriasis
Marrakchi, S, Puig, L. Pathophysiology of Generalized Pustular Psoriasis. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(SUPPL 1)DOI:10.1007/s40257-021-00655-y. PMID:35061228. IF:7.300(Q1/1D).
01/01/2022
Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey (Oct, 10.1007/s13555-021-00635-4, 2021)
Lebwohl, M, Langley, RG, Paul, C, Puig, L, Reich, K, van de Kerkhof, P, Wu, HL, Richter, S, Jardon, S, Gisondi, P. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey (Oct, 10.1007/s13555-021-00635-4, 2021). Dermatology and Therapy. 2022; 12(1)DOI:10.1007/s13555-021-00656-z. PMID:34989998. IF:3.400(Q2/3D).
01/01/2022
Nodular scabies mimicking breast cancer skin metastasis
Cubiro, X, Garcia-Melendo, C, Tubau-Prims, C, Puig, L. Nodular scabies mimicking breast cancer skin metastasis. Indian Journal of Dermatology Venereology & Leprology. 2022; 88(1)DOI:10.25259/IJDVL_63_2021. PMID:34623049. IF:2.900(Q2/4D).
01/12/2021
Integra as Firstline Treatment for Scalp Reconstruction in Elderly Patients
Mogedas-Vegara, A, Agut-Busquet, E, Marsal, MY, Aguilar, JL, de la Torre, OE. Integra as Firstline Treatment for Scalp Reconstruction in Elderly Patients. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY. 2021; 79(12)DOI:10.1016/j.joms.2021.07.009. PMID:34391723. IF:2.136(Q4/8D).
01/11/2021
Ultrasonographic patterns of cutaneous sarcoidosis
Lopez-Llunell, C, Romani, J, Roe, E, Giavedoni, P, Vidal, D, Wortsman, X. Ultrasonographic patterns of cutaneous sarcoidosis. JOURNAL OF ULTRASOUND IN MEDICINE. 2021; 40(11)DOI:10.1002/jum.15631. PMID:33459396. IF:2.754(Q2/4D).
01/11/2021
New perspectives on the treatment of hidradenitis suppurativa
Amat-Samaranch, V, Agut-Busquet, E, Vilarrasa, E, Puig, L. New perspectives on the treatment of hidradenitis suppurativa. Therapeutic Advances in Chronic Disease. 2021; 12DOI:10.1177/20406223211055920. PMID:34840709. IF:4.970(Q2/3D).
01/11/2021
Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study
Mercader-Garcia, P, Pastor-Nieto, MA, Gonzalez-Perez, R, Cordoba-Guijarro, S, Gimenez-Arnau, AM, Ruiz-Gonzalez, I, Mora-Fernandez, V, Miquel, J, Silvestre-Salvador, JF, Ortiz-Frutos, FJ, Sanz-Sanchez, T, Rodriguez-Serna, M, Perez-Feal, P, Sanchez-Perez, J, Heras-Mendaza, F, Serra-Baldrich, E, Zaragoza-Ninet, V, Hervella-Garces, M, Gatica-Ortega, ME, Garcia-Doval, I, Descalzo, MA, Borrego, L. Should methyldibromo glutaronitrile continue to be used in the European baseline Series? A REIDAC national cross-sectional study. CONTACT DERMATITIS. 2021; 85(5)DOI:10.1111/cod.13837. PMID:33745152. IF:6.419(Q1/1D).
01/11/2021
Sequelae following infantile haemangiomas treated with propranolol
Baselga, E, El Hachem, M, Diociaiuti, A, Carnevale, C, Downey, C, Roe, E, Mascaro, P, Neri, I, Leuzzi, M, Bernabeu-Wittel, J, Monserrat-Garcia, MT, Ortiz-Prieto, A, Torrelo, A, Knopfel, N, Vercellino, N, Manunza, F, Oranges, T, Bassi, A, Gonzalez-Ensenat, MA, Vicente, A, Gich, I, Puig, L. Sequelae following infantile haemangiomas treated with propranolol. EUROPEAN JOURNAL OF DERMATOLOGY. 2021; 31(6)DOI:10.1684/ejd.2021.4172. PMID:35107070. IF:2.805(Q2/5D).
01/08/2021
Quality of Life in Hidradenitis Suppurativa: Validation of the HSQoL-24
Marron, SE, Gomez-Barrera, M, Aragones, LT, Goni-Navarro, A, Vilarrasa-Rull, E, Diaz-Diaz, RM, Garcia-Latasa De Aranibar, FJ, Campos-Rodenas, R, Fuentelsaz-Del Barrio, V, Gilaberte-Calzada, Y, Gracia-Cazana, T, Morales-Callaghan, AM, Ros-Abarca, S, Madrid-Alvarez, MB, Puig, L. Quality of Life in Hidradenitis Suppurativa: Validation of the HSQoL-24. ACTA DERMATO-VENEREOLOGICA. 2021; 101DOI:10.2340/00015555-3905. PMID:34427316. IF:3.875(Q2/3D).
01/07/2021
Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study
Torres, T, Puig, L, Vender, R, Lynde, C, Piaserico, S, Carrascosa, JM, Gisondi, P, Dauden, E, Conrad, C, Mendes-Bastos, P, Ferreira, P, Leite, L, Lu, JSD, Valerio, J, Bruni, M, Messina, F, Nidegger, A, Llamas-Velasco, M, del Alcazar, E, Mufti, A, White, K, Caldarola, G, Teixeira, L, Romanelli, P, Desai, K, Gkalpakiotis, S, Romanelli, M, Yeung, JN, Nogueira, M, Chiricozzi, A. Drug Survival of IL-12/23, IL-17 and IL-23 Inhibitors for Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2021; 22(4)DOI:10.1007/s40257-021-00598-4. PMID:33786754. IF:6.233(Q1/2D).
01/07/2021
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey
Mahil, SK, Yates, M, Langan, SM, Yiu, ZZN, Tsakok, T, Dand, N, Mason, KJ, McAteer, H, Meynell, F, Coker, B, Vincent, A, Urmston, D, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Bachelez, H, Bruce, IN, Capon, F, Contreras, CR, Cope, AP, de la Cruz, C, Di Meglio, P, Gisondi, P, Hyrich, K, Jullien, D, Lambert, J, Marzo-Ortega, H, McInnes, I, Naldi, L, Norton, S, Puig, L, Sengupta, R, Spuls, P, Torres, T, Warren, RB, Waweru, H, Weinman, J, Griffiths, CEM, Barker, JN, Brown, MA, Galloway, JB, Smith, CH, PsoProtect CORE-UK Study Grp. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. BRITISH JOURNAL OF DERMATOLOGY. 2021; 185(1)DOI:10.1111/bjd.19755. PMID:33368145. IF:11.113(Q1/1D).
01/01/2023
High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting
Martos-Cabrera, L, Llamas-Velasco, M, Armesto, S, Herrera-Acosta, E, Vidal, D, Vilarrasa, E, Rivera-Diaz, R, de la Cueva, P, Martorell-Calatayud, A, Ballesca, F, Belinchon, I, Carretero, G, Rodriguez, L, Romero-Mate, A, Pujol-Montcusi, J, Salgado-Boquete, L, Sahuquillo-Torralba, A, Coto-Segura, P, Baniandres, O, Feltes, R, Alsina, M, Dauden, E. High adherence to secukinumab in patients with moderate to severe psoriasis: a long-term multicenter study in a daily practice setting. INTERNATIONAL JOURNAL OF DERMATOLOGY. 2023; 62(3)DOI:10.1111/ijd.16365. PMID:35867958. IF:3.500(Q1/3D).
01/01/2023
Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry
Muniesa C., Gallardo F., García-Doval I., Estrach M.T., Combalia A., Morillo-Andújar M., De la Cruz-Vicente F., Machan S., Moya-Martínez C., Rovira R., Sanchez-Gonzalez B., Acebo E., Amutio E., Penate, Y, Losada-Castillo, MD, García-Muret M.P., Iznardo H., Román-Curto C., Canueto, J, Fernández-de-Misa R., Flórez Á., Izu R.M., Torres-Navarro I., Zayas A., Pérez-Paredes G., Blanes M., Yanguas J.I., Pérez-Ferriols A., Callejas-Charavia M., Ortiz-Romero P.L., Pérez-Gil A., Prieto-Torres L., González-Barca E., Servitje O.. Brentuximab vedotin in the treatment of cutaneous T-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2023; 37(1)DOI:10.1111/jdv.18563. PMID:36017748. IF:8.500(Q1/1D).
01/12/2022
Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate
Tubau, C, Cubiro, X, Amat-Samaranch, V, Garcia-Melendo, C, Puig, L, Roe-Crespo, E. Clinical and ultrasonography follow-up of five cases of calcinosis cutis successfully treated with intralesional sodium thiosulfate. Journal Of Ultrasound. 2022; 25(4)DOI:10.1007/s40477-022-00665-4. PMID:35397096. IF:(Q/D).
01/12/2022
Psoriasis treatment: no more room on the summit?
Puig, L. Psoriasis treatment: no more room on the summit?. BRITISH JOURNAL OF DERMATOLOGY. 2022; 187(6)DOI:10.1111/bjd.21848. PMID:36065496. IF:10.300(Q1/1D).
01/12/2022
A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis
Armstrong, AW, Soliman, AM, Betts, KA, Wang, Y, Gao, YW, Stakias, V, Puig, L. A Response to: Letter to the Editor Regarding Long-Term Benefit-Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-analysis. Dermatology and Therapy. 2022; 12(12)DOI:10.1007/s13555-022-00812-z. PMID:36271222. IF:3.400(Q2/3D).
01/11/2022
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)
Pinter, A, Puig, L, Schakel, K, Reich, A, Zaheri, S, Costanzo, A, Tsai, TF, Smith, SD, Lynde, C, Brnabic, A, Reed, C, Hill, J, Schuster, C, Riedl, E, Paul, C. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11)DOI:10.1111/jdv.18376. PMID:35766124. IF:9.200(Q1/1D).
01/11/2022
SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis
Sans-De San Nicolas, L, Figueras-Nart, I, Bonfill-Orti, M, De Jesus-Gil, C, Garcia-Jimenez, I, Guilabert, A, Curto-Barredo, L, Bertolin-Colilla, M, Ferran, M, Serra-Baldrich, E, Zalewska-Janowska, A, Wang, YH, Howell, MD, Pujol, RM, Santamaria-Babi, LF. SEB-induced IL-13 production in CLA(+) memory T cells defines Th2 high and Th2 low responders in atopic dermatitis. ALLERGY. 2022; 77(11)DOI:10.1111/all.15424. PMID:35773619. IF:12.400(Q1/1D).
01/11/2022
Deucravacitinib for the Treatment of Psoriatic Disease
Le, AM, Puig, L, Torres, T. Deucravacitinib for the Treatment of Psoriatic Disease. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6)DOI:10.1007/s40257-022-00720-0. PMID:35960487. IF:7.300(Q1/1D).
01/11/2022
Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study
Torres, T, Puig, L, Vender, R, Yeung, J, Carrascosa, JM, Piaserico, S, Gisondi, P, Lynde, C, Ferreira, P, Bastos, PM, Dauden, E, Leite, L, Valerio, J, del Alcazar-Viladomiu, E, Rull, EV, Llamas-Velasco, M, Pirro, F, Messina, F, Bruni, M, Licata, G, Ricceri, F, Nidegger, A, Hugo, J, Mufti, A, Daponte, AI, Teixeira, L, Balato, A, Romanelli, M, Prignano, F, Gkalpakiotis, S, Conrad, C, Lazaridou, E, Rompoti, N, Papoutsaki, M, Nogueira, M, Chiricozzi, A. Drug Survival of Interleukin (IL)-17 and IL-23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi-country, Multicentric Cohort Study. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY. 2022; 23(6)DOI:10.1007/s40257-022-00722-y. PMID:35976568. IF:7.300(Q1/1D).
01/11/2022
European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations
Wollenberg, A, Kinberger, M, Arents, B, Aszodi, N, Valle, GA, Barbarot, S, Bieber, T, Brough, HA, Pinton, PC, Christen-Zach, S, Deleuran, M, Dittmann, M, Dressler, C, Fink-Wagner, AH, Fosse, N, Gaspar, K, Gerbens, L, Gieler, U, Girolomoni, G, Gregoriou, S, Mortz, CG, Nast, A, Nygaard, U, Redding, M, Rehbinder, EM, Ring, J, Rossi, M, Serra-Baldrich, E, Simon, D, Szalai, ZZ, Szepietowski, JC, Torrelo, A, Werfel, T, Flohr, C. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(11)DOI:10.1111/jdv.18429. PMID:36056736. IF:9.200(Q1/1D).
01/10/2022
Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies
Thaci, D, Gerdes, S, Du Jardin, KG, Perrot, JL, Puig, L. Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies. Dermatology and Therapy. 2022; 12(10)DOI:10.1007/s13555-022-00793-z. PMID:36098877. IF:3.400(Q2/3D).
01/09/2022
European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy
Wollenberg, A, Kinberger, M, Arents, B, Aszodi, N, Valle, GA, Barbarot, S, Bieber, T, Brough, HA, Pinton, PC, Christen-Zach, S, Deleuran, M, Dittmann, M, Dressler, C, Fink-Wagner, AH, Fosse, N, Gaspar, K, Gerbens, L, Gieler, U, Girolomoni, G, Gregoriou, S, Mortz, CG, Nast, A, Nygaard, U, Redding, M, Rehbinder, EM, Ring, J, Rossi, M, Serra-Baldrich, E, Simon, D, Szalai, ZZ, Szepietowski, JC, Torrelo, A, Werfel, T, Flohr, C. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(9)DOI:10.1111/jdv.18345. PMID:35980214. IF:9.200(Q1/1D).
01/09/2022
HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience
Piron, M, Salvador, F, Caballero, E, Sanchez-Montalva, A, Bes, M, Casamitjana, N, Puig, L, Molina, I, Sauleda, S. HTLV-1/2 Infection in Blood Donors from a Non-Endemic Area (Catalonia, Spain) between 2008 and 2017: A 10-Year Experience. Viruses-Basel. 2022; 14(9)DOI:10.3390/v14091975. PMID:36146780. IF:4.700(Q2/5D).
18/08/2022
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis
Zozaya, N, Abdalla, F, Zamora, SA, Filgueiras, JB, Carrillo, JMC, Sanchez, OD, Sinisterra, FD, Garcia-Ruiz, A, Pinto, PH, Manfredi, A, Olmos, JM, Luna, PMD, Puig, L, Ros, S, HIdalgo-Vega, A. Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert Review of Pharmacoeconomics & Outcomes Research. 2022; 22(6)DOI:10.1080/14737167.2022.2063842. PMID:35404728. IF:2.300(Q3/7D).
18/08/2022
Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group
del Alcazar, E, Lopez-Ferrer, A, Martinez-Domenech, A, Julia, M, Ruiz-Villaverde, R, Fernandez-Freire, LR, Notario, J, Llamas-Velasco, M, Ferran, M, Carrascosa, JM. Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(6)DOI:10.1080/09546634.2022.2079596. PMID:35593480. IF:2.900(Q2/4D).
01/08/2022
Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa
Iznardo, H, Vilarrasa, E, Roe, E, Puig, L. Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8)DOI:10.1111/jdv.18116. PMID:35353931. IF:9.200(Q1/1D).
01/08/2022
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3
Reich, K, Iversen, L, Puig, L, Lambert, J, Mrowietz, U, Saday, KK, Warren, RB. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and-3. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2022; 36(8)DOI:10.1111/jdv.18068. PMID:35279890. IF:9.200(Q1/1D).
01/08/2022
Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting
Chicharro, P, Llamas-Velasco, M, Armesto, S, Herrera-Acosta, E, Vidal, D, Vilarrasa, E, Rivera, R, De la Cueva, P, Martorell-Calatayud, A, Ballesca, F, Belinchon, I, Carretero, G, Rodriguez, L, Romero-Mate, A, Pujol-Montcusi, J, Salgado, L, Sahuquillo-Torralba, A, Coto-Segura, P, Baniandres-Rodriguez, O, Feltes, R, Alsina, M, Dauden, E. Fast and sustained improvement of patient-reported outcomes in psoriatic patients treated with secukinumab in a daily practice setting. Dermatologic Therapy. 2022; 35(8)DOI:10.1111/dth.15653. PMID:35731640. IF:3.600(Q1/3D).
01/08/2022
IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications
Iznardo, H, Puig, L. IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(16)DOI:10.3390/ijms23169479. PMID:36012744. IF:5.600(Q1/3D).
04/07/2022
Comorbidity identification and referral in atopic dermatitis: a consensus document
de Frutos, JO, Carretero, G, de Lucas, R, Puig, S, Serra, E, Castro, SG, Laserna, FR, Loza, E, Silvestre-Salvador, JF. Comorbidity identification and referral in atopic dermatitis: a consensus document. JOURNAL OF DERMATOLOGICAL TREATMENT. 2022; 33(5)DOI:10.1080/09546634.2022.2067815. PMID:35435103. IF:2.900(Q2/4D).
01/07/2022
Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract
Amat-Samaranch, V, Lopez-Sanchez, C, Tubau, C, Puig, L, Serra-Baldrich, E. Vulvar allergic contact dermatitis caused by Magnolia officinalis bark extract. CONTACT DERMATITIS. 2022; 87(1)DOI:10.1111/cod.14101. PMID:35277988. IF:5.500(Q1/1D).
01/07/2022
Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain
Colmenero, M, del Boz, J, Wittel, JB, Roe, E, Feito-Rodriguez, M, Vicente-Villa, MA, Martin-Santiago, A, Perez, SIP, Azon, A, Valdivielso-Ramos, M, Torrelo, A, Moya, AIS, Campos-Dominguez, M, Garnacho-Saucedo, G, Defez, JMA, Casano, AV, Tercedor-Sanchez, J, Alcala, R, Gonzalez-Enseyat, MA, Giacaman, A, Hernandez-Martin, A, Garcia, MTM, Bauza, A, Dominguez-Cruz, J, Garcia-Doval, I, Grau-Perez, M. Inter- and intra-observer variability in the selection of therapy for infantile hemangiomas among pediatric dermatologists in Spain. PEDIATRIC DERMATOLOGY. 2022; 39(4)DOI:10.1111/pde.15015. PMID:35504688. IF:1.500(Q4/8D).